Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Early Glargine

Phase 3Small molecule

TThe Cleveland Clinic

1

Indications

2

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Multiple Sclerosis, Relapsing-RemittingActive, not recruiting

Multiple Sclerosis, Relapsing-RemittingPhase 3

Active, not recruiting

Timeline

Expected Milestones

Q3 2027

ApprovedActive, not recruiting

Multiple Sclerosis, Relapsing-Remitting

NCT03535298

Clinical

Trials by Indication[1]

Diabetic Ketoacidosis1 trial

Early Basal Insulin Administration in Adult Diabetic Ketoacidosis Management

Terminated·TThe Cleveland Clinic·Phase 4·NCT04567225·39 enrolled

Multiple Sclerosis, Relapsing-Remitting1 trial

Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for the Treatment of Relapsing-Remitting Multiple Sclerosis

Active, not recruiting·TThe Cleveland Clinic·Approved·NCT03535298·800 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Early Glargine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Early Glargine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Early Glargine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The Cleveland Clinic company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: TThe Cleveland Clinic

Related News